Elevation Oncology discontinues EO-3021 development due to insufficient efficacy in phase 1 trial, despite favorable safety profile. EO-3021 trial showed a 22.2% objective response rate and 72.2% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results